Summary & Overview

CPT 0623U: TruD MDS Multiple Sclerosis DNA Methylation Test

CPT code 0623U represents a Proprietary Laboratory Analyses (PLA) molecular diagnostic test: the TruD MDS Multiple Sclerosis assay from TruDiagnostic™ Inc. The test evaluates DNA methylation at over 5,000 sites from a whole blood sample and classifies results as a positive or negative risk for multiple sclerosis. As a PLA code, 0623U is specific to a single manufacturer’s assay and is used nationally to identify and bill for this unique laboratory service.

Key payers considered in this publication include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for the assay, the service and typical site of service, and what the PLA designation means for coding and payer identification. The guide outlines expected topics covered in the fuller publication: national coverage and reimbursement benchmarks where available, payer coverage considerations, coding and billing implications for laboratories and ordering clinicians, and the clinical utility of DNA methylation profiling in autoimmune (multiple sclerosis) risk reporting.

Data not provided in the input are noted explicitly in the relevant sections of the full publication. The summary is intended for national audiences seeking a clear understanding of what CPT code 0623U denotes and where it fits in laboratory molecular diagnostics for multiple sclerosis.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicare0623UCPTProprietary Laboratory Analysesmolecular diagnosticDNA methylationmultiple sclerosislaboratory testPLA codewhole blood

Billing Code Overview

CPT code 0623U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to the TruD MDS Multiple Sclerosis test from TruDiagnostic™ Inc. The assay analyzes DNA methylation at more than 5,000 sites using a whole blood sample and uses an algorithm to report a positive or negative risk result for autoimmune multiple sclerosis.

Service Type: Clinical laboratory molecular diagnostic test using DNA methylation profiling.

Typical Site of Service: Clinical laboratory or point-of-care collection site with whole blood specimen collection (e.g., outpatient phlebotomy, physician office, or independent laboratory collection site).

Clinical & Coding Specifications

Clinical Context

A 38-year-old patient with a 6-month history of intermittent numbness, gait imbalance, and visual disturbances presents to a neurology clinic for evaluation of possible multiple sclerosis (MS). Prior workup includes neurologic examination, MRI of the brain and spinal cord showing nonspecific white matter lesions, and lumbar puncture with equivocal oligoclonal band results. The neurologist orders the proprietary methylation-based blood test 0623U (TruD MDS Multiple Sclerosis, TruDiagnostic™ Inc.) to aid in assessment of autoimmune risk by analyzing DNA methylation at >5,000 CpG sites in whole blood and reporting a positive or negative risk result.

Clinical workflow:

The clinician documents clinical indication and obtains informed consent for the proprietary laboratory analysis.
A whole blood sample is collected in the facility’s phlebotomy area or outpatient lab and prepared per the manufacturer’s collection and shipping instructions.
The specimen is shipped to TruDiagnostic™ Inc. for processing. The laboratory performs DNA extraction, methylation profiling, and applies the proprietary algorithm to generate a positive/negative risk report for MS-related autoimmune signal.
The laboratory report is returned to the ordering clinician and integrated into the patient’s chart.
The ordering clinician interprets the result in context with MRI, cerebrospinal fluid studies, and clinical criteria to inform diagnostic impressions and ongoing management planning.

Typical site of service: outpatient neurology clinic, outpatient phlebotomy laboratory, or independent clinical laboratory performing the PLA service.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	Use when reporting only the professional interpretation component separate from the laboratory technical processing (rare for PLA codes).
`90`	Reference (outside) laboratory	Use when the specimen is sent to an outside clinical laboratory performing the test.
`91`	Repeat clinical diagnostic laboratory test	Use when the same test is repeated on the same day to confirm prior analytic result when clinically necessary.
`52`	Reduced services	Use when the laboratory test is performed but reduced or not completed as originally described.
`59`	Distinct procedural service	Use when another distinct, separate service is provided on the same day and needs differentiation from the PLA service.
`76`	Repeat procedure by same provider	Use when the laboratory test is repeated by the same provider later the same day.
`77`	Repeat procedure by another provider	Use when the laboratory test is repeated by a different provider the same day.
`24`	Unrelated evaluation and management service on the same day	Use when an unrelated E/M service is furnished the same day as the lab order and must be reported separately.
`TC`	Technical component	Use when billing only the technical component of the test (equipment, supplies, processing) if separately reportable.
`QW`	CLIA waived test	Not applicable to this PLA but included for completeness; do not use unless test meets CLIA waived criteria.

Taxonomy Code	Specialty	Notes
`2084P0800X`	Neurology	Neurologists commonly order MS diagnostic testing and interpret results in clinical context.
`207P00000X`	Psychiatry & Neurology	Neurology-focused practitioners evaluating neuroimmunologic conditions.
`363LP0800X`	Clinical Laboratory Director	Laboratory professionals responsible for oversight of specialized molecular diagnostic testing.
`261QP2300X`	Internal Medicine	Primary care internists may order or coordinate specialty testing for diagnostic evaluation.
`207K00000X`	Physical Medicine & Rehabilitation	Specialists who may be involved in functional assessment and referral for diagnostic testing.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`G35`	Multiple sclerosis	Primary diagnosis for which methylation-based risk testing for autoimmune signal may be ordered.
`G37.9`	Demyelinating disease of central nervous system, unspecified	Used when demyelinating process is suspected but MS criteria are not yet met; supports ordering advanced diagnostic tests.
`R20.2`	Paresthesia of skin	Symptom commonly prompting neurologic evaluation and consideration of MS testing.
`H46`	Optic neuritis	Acute optic neuritis is frequently associated with MS and may prompt ordering of supportive diagnostic assays.
`G04.89`	Other encephalitis, myelitis and encephalomyelitis	Used for inflammatory CNS conditions where autoimmune methylation profiling may be considered as part of differential.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`80307`	Drug assay, presumptive, any number of drug classes; any specimen except urine, performed by laboratory instrument system	Not specific to PLA testing; occasionally performed when medication effects confound neurologic symptoms.
`83912`	Molecular diagnostic sequencing procedure, methylation analysis, genome-scale; whole genome or global methylation profile (when reported)	Related analytic methodology; PLA `0623U` uses targeted methylation profiling but may conceptually align with methylation sequencing services.
`99000`	Handling and/or conveyance of specimen for transfer between facilities (non-covered)	May be reported for specimen transport logistics when applicable to complex external lab coordination.
`36415`	Collection of venous blood by venipuncture	Performed at the time of ordering `0623U` to obtain the whole blood specimen for analysis.
`99070`	Supplies and materials (e.g., catheter, sterile tray) for routine venipuncture when not included	May be used to report additional required supplies for blood collection if payer allows separate reporting.